Scarica l'app Stockscreener
9.01
0.45%
0.04
Dopo l'orario di chiusura:
9.17
0.16
+1.78%
Precedente Chiudi:
$8.97
Aprire:
$8.92
Volume 24 ore:
3.03M
Relative Volume:
2.14
Capitalizzazione di mercato:
$700.65M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-4.3951
EPS:
-2.05
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
-6.44%
1M Prestazione:
-43.37%
6M Prestazione:
-55.66%
1 anno Prestazione:
-27.04%
Intervallo 1D:
$8.88
$9.17
Intervallo di 1 settimana:
$8.85
$10.02
Portata 52W:
$8.85
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.01 | 700.65M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology expands stock option plan - Investing.com
Kura Oncology (NASDAQ:KURA) Reaches New 52-Week LowWhat's Next? - MarketBeat
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade) (NASDAQ:KURA) - Seeking Alpha
(KURA) Proactive Strategies - Stock Traders Daily
Kura Oncology's SWOT analysis: ziftomenib's promise buoys stock outlook By Investing.com - Investing.com UK
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook By Investing.com - Investing.com South Africa
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook - Investing.com India
Kura Oncology's SWOT analysis: ziftomenib's potential reshapes cancer stock landscape - Investing.com Canada
Kura Oncology’s (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting - The Manila Times
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting - Marketscreener.com
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Kura O - GuruFocus.com
Purple Biotech Secures $2.8 Million for Oncology Advancements - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Kura Oncology Inc (NASDAQ: KURA) Gains 1.45% In Early Trade; What Lies Ahead? - Stocks Register
Kura Oncology to Host Virtual Investor Event on December 9, 2024 - The Manila Times
Kura Oncology to Host Investor Event on Ziftomenib Clinical Trial Data from ASH Meeting | KURA Stock News - StockTitan
ImmuneOnco Raises Funds for Cancer Research - MSN
Kura Oncology price target raised to $37 from $32 at H.C. Wainwright - MSN
Kura Oncology’s Collaboration with Kyowa Kirin - Global Legal Chronicle
How to Take Advantage of moves in (KURA) - Stock Traders Daily
Kura Oncology's SWOT analysis: precision cancer drug stock faces pivotal year - Investing.com India
Kura, Kyowa Kirin to co-develop ziftomenib in $1.49B deal - BioWorld Online
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit - The Manila Times
Kura Oncology CEO to Present at JMP Securities Hematology & Oncology Summit | KURA Stock News - StockTitan
Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Given Buy Rating at TD Cowen - Defense World
FY2025 EPS Estimate for Kura Oncology Raised by Analyst - Defense World
Leerink Partnrs Predicts Stronger Earnings for Kura Oncology - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
Brokers Offer Predictions for Kura Oncology FY2025 Earnings - MarketBeat
Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology partners Kyowa Kirin to advance AML treatment - MSN
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover - MSN
Kura Oncology (NASDAQ:KURA) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Stifel cuts Kura Oncology target to $11 from $18, holds rating - Investing.com Canada
Firm Advises Kura Oncology on Global Strategic Collaboration with Kyowa Kirin - Wilson Sonsini
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Kura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely Bullish - MSN
Kura Oncology (NASDAQ:KURA) Given New $29.00 Price Target at Bank of America - MarketBeat
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 By Investing.com - Investing.com South Africa
Kura Oncology (NASDAQ:KURA) Shares Gap Down on Analyst Downgrade - Defense World
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 - Investing.com India
Kura Oncology inks global deal with Kyowa Kirin By Investing.com - Investing.com Nigeria
Analysts supportive of Kura/Kirin deal despite major selloff (update) - MSN
Health Care Roundup: Market Talk - MSN
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - MedCity News
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):